project id: TCGA-PRAD; case submitter id: TCGA-ZG-A9KY; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.65; rna integrity number: 8.1; age at index: 73; days to birth: -27000; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1940; age at diagnosis: 27000; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N1; ajcc pathologic t: T4; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 130.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 112; initial weight: 120.0; sample id: 680b539d-25c4-4f00-9b1a-904f90c148c4; sample submitter id: TCGA-ZG-A9KY-01A; portion id: 3482d1f7-bc82-4dd6-8921-129a8515d357; portion submitter id: TCGA-ZG-A9KY-01A-11; slide id: 19ddb515-c828-4753-987a-1b44fb773ded; slide submitter id: TCGA-ZG-A9KY-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 20.0; percent tumor cells: 70.0; percent tumor nuclei: 80.0; section location: TOP;